- Advanced Medical Solutions Group
- 15 January 2026 13:11:50
Source: Sharecast
The AIM-traded group said revenue for the year ended 31 December was expected to rise to £228.5m, up from £177.5m in 2024, while EBITDA was forecast to be in the range of £49.5m to £50m, compared with £40.2m a year earlier.
It said performance in its surgical portfolio remained strong throughout the year, while improvements in woundcare offset some destocking in the Peters Surgical B2B business.
AMS said the integration of Peters Surgical and Syntacoll continued to progress as planned.
Commercial synergies contributed positively during 2025, while operational synergies remained on track to be realised from 2027 onwards.
“Our surgical business has recorded another period of strong performance, and we have also benefited from the restructuring of our woundcare franchise,” said chief executive Chris Meredith.
“Our portfolio is now broader and stronger than at any point in the group's history, and our pipeline includes a number of exciting and significant opportunities for future growth.”
He added that the integration of Peters Surgical had accelerated the group’s geographic expansion and that plans for further penetration of the US market were well advanced.
The company said it intended to publish its full-year results on 18 March and remained confident of delivering another strong performance in 2026, supported by sustained momentum across the business.
At 1242 GMT, shares in Advanced Medical Solutions Group were up 1.8% at 226p.
Reporting by Josh White for Sharecast.com.